Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing NMO.


Clinical Trial Description

This study is an open label extension study to confirm the long term safety and efficacy of eculizumab in subjects with relapsing NMO who have completed the initial double-blind, randomized, placebo-controlled trial ECU-NMO-301. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02003144
Study type Interventional
Source Alexion Pharmaceuticals
Contact
Status Completed
Phase Phase 3
Start date January 12, 2015
Completion date July 12, 2021

See also
  Status Clinical Trial Phase
Completed NCT02283671 - Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B Phase 1
Recruiting NCT01024985 - Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct N/A
Recruiting NCT04601142 - Association Between the Effect of Glucocorticoid Pulse Therapy on Neuromyelitis Optica (NMO) and Gene Polymorphism
Completed NCT03942952 - PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.
Recruiting NCT05573711 - Restless Legs Syndrome in People With Neuromyelitis Optica Spectrum Disorder
Not yet recruiting NCT06118398 - Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders
Recruiting NCT05566769 - Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD N/A
Withdrawn NCT03829566 - Autologous Transplant To End NMO Spectrum Disorder Phase 2/Phase 3
Recruiting NCT05403138 - Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders Phase 2/Phase 3
Completed NCT03350633 - Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders Phase 2/Phase 3
Recruiting NCT05356858 - An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients Phase 2
Recruiting NCT05982925 - Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders
Active, not recruiting NCT00445367 - Biobank For MS And Other Demyelinating Diseases
Terminated NCT02398994 - A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Phase 3
Withdrawn NCT02087813 - Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses Phase 1
Terminated NCT01339455 - Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica Phase 1/Phase 2
Recruiting NCT02021825 - Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Phase 4
Active, not recruiting NCT04614454 - High Frequency Impulse Therapy for Neuropathic Pain in NMOSD Phase 2
Recruiting NCT03370965 - Optic Neuritis Differential Diagnosis Study N/A
Completed NCT01777412 - Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations Phase 1